Zivo Bioscience (Zivo Bioscience) ROCE % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Zivo Bioscience ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zivo Bioscience's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.

Zivo Bioscience ROCE % Historical Data

The historical data trend for Zivo Bioscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zivo Bioscience ROCE % Chart

Zivo Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-284.57

Zivo Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Zivo Bioscience ROCE % Calculation

Zivo Bioscience's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-7.263	/	( ( (2.123 - 2.028)	+	(0.556 - 2.762) )	/ 2 )
	=	-7.263	/	( (0.095	+	-2.206)	/ 2 )
	=	-7.263	/	-1.0555
	=	688.11 %

Zivo Bioscience's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-5.104	/	( ( (0.556 - 2.762)	+	(0.816 - 3.085) )	/ 2 )
	=	-5.104	/	( ( -2.206	+	-2.269 )	/ 2 )
	=	-5.104	/	-2.2375
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Zivo Bioscience (OTCPK:ZIVO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zivo Bioscience ROCE % Related Terms

Thank you for viewing the detailed overview of Zivo Bioscience's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zivo Bioscience (Zivo Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zivo Bioscience Inc (OTCPK:ZIVO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

21 East Long Lake Road, Suite 100, Bloomfield Hills, MI, USA, 48304

Website

https://www.zivobioscience.com

Zivo Bioscience Inc is a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company's pipeline candidates are; Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Human Food Ingredients, and Skin Health.

Executives

Alison A Cornell	director	210 CARNEGIE CENTER, PRINCETON NJ 08540
Christopher D. Maggiore	officer: CHIEF FINANCIAL OFFICER	4788 NOBLES POND DR. NW, CANTON OH 44718
Nola E Masterson	director	768 WEST CALIFORNIA WAY, WOODSIDE CA 94062
John Bernard Payne	director	9900 NE 114TH CIRCLE, VANCOUVER WA 98662
Strome Mezzanine Fund, Lp	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Keith Marchiando	officer: Chief Financial Officer	C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304
Mark E Strome	10 percent owner	100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401
Strome Alpha Fund L P	10 percent owner	100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401
Strome Investment Management Lp	10 percent owner	100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401
Strome Group, Inc.	10 percent owner	100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401
Hep Investments Llc	10 percent owner	2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320
Rondeau Robert O Jr	director	70 WEST LONG LAKE RD, STE 119, TROY MI 48098
Thomas Kevin Cox	director	470 MICHGAMME LANE, LAKE FOREST IL 60045
Andrew A Dahl	officer: President, CEO	7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302
Brian W Young	other: See remarks below.	1800 NW CORPORATE BLVD, BOCA RATON FL 33431